Companies /Healthcare
Gilead Sciences Inc
NASDAQ: GILD Drug Manufacturers - General
$156.19
▼ $1.18 (−0.75%) today
Markets closed · 3:51pm ET

Gilead Sciences (GILD) Earnings History & Trends

EPS and revenue vs. Street estimates · SEC filings
100%
EPS beat rate
+5.92%
Avg. EPS surprise
Consecutive EPS beats
GILD vs Market · 30-day return after each reportGILDS&P 500
−7%0%+7%+14%+5.1%+6.7%Q1 25−3.5%+2.4%Q2 25+4.4%+0.3%Q3 25−6.8%−3.3%Q4 25−7.5%−1.7%Q1 26+14.6%+0.1%Q2 26
−7%0%+7%+14%Q1 25Q3 25Q1 26
GILD EPS Trend · estimate vs actualEstimateActual
$-6$-3$0$1.77$1.81Q1 25$1.96$2.01Q2 25$2.14$2.47Q3 25$1.83$1.86Q4 25$1.91$2.03Q1 26$-7.25$-6.75Q2 26
$-6$-3$0Q1 25Q3 25Q1 26
GILD Revenue Trend · estimate vs actualEstimateActual
$0$3.0B$6.0B$6.8B$6.7BQ1 25$7.0B$7.1BQ2 25$7.5B$7.8BQ3 25$7.7B$7.9BQ4 25$6.9B$7.0BQ1 26$7.4B$7.8BQ2 26
$0$3.0B$6.0BQ1 25Q3 25Q1 26

How Often Does Gilead Sciences Beat Earnings Estimates?

Gilead Sciences beat EPS estimates in 6 of its last 6 reported quarters, and has beaten 6 quarters in a row.

GILD quarterly earnings per share and revenue versus Street estimates
Quarter EPS · est. Surprise Revenue · est. Surprise
Q2 2026 Includes $(9.08) per share impact of acquired IPR&D expenses of $11.1 billion related to Arcellx, Tubulis, and Ouro Medicines acquisitions, net of Lakefront collaboration impact and related taxes, plus $1.07 per share IPR&D impairment related to previously acquired Immunomedics assets $-6.75 est. $-7.25 +6.86% $7.8B est. $7.4B +5.41%
Q1 2026 $2.03 est. $1.91 +6.30% $7.0B est. $6.9B +0.51%
Q4 2025 $1.86 est. $1.83 +1.88% $7.9B est. $7.7B +3.21%
Q3 2025 $2.47 est. $2.14 +15.67% $7.8B est. $7.5B +4.14%
Q2 2025 $2.01 est. $1.96 +2.72% $7.1B est. $7.0B +1.69%
Q1 2025 $1.81 est. $1.77 +2.11% $6.7B est. $6.8B −2.14%

Figures from SEC filings and company reports. Not investment advice.